A fundamental change in drug biodistribution and performance.

TRX’s technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and developmentally proven approach.

TRx Technology

Radical approaches to drug absorption, transport and destination.

A disruptive advancement in oral drug uptake, trafficking therapeutics directly to the site of disease, reducing the impact of first-pass metabolism and enhancing production of regulatory immune cells. TRx is leveraging these and other benefits across a growing portfolio of co-development and wholly-owned programmes.

TRx Pipeline

Why TRx?

Potential to transform the design, delivery and development of small molecule-based oral therapies
Exploitation of a novel oral drug uptake channel that utilises existing human biology
Transcend state-of-the-art oral drug delivery technologies
Bring unexploitable pharmacology to clinical significance
Clinically proven technology, rapidly deployable and manufacturable at scale
Robust and long-term IP protection
For partners, a proven track record in solving complex pharmacokinetic and pharmacodynamic limitations for lead clinical programmes

TRx Strategy

TRx Technology.

1. Absorption

Utilise unexploited uptake channels solving historic limitations in drug absorption using existing human biology
High drug load into chylomicrons prior to systemic distribution

2. Transport

Avoidance of first pass metabolism and sustained metabolic protection
Priming of key immune cells followed wider drug distribution commencing with lung and brain

3. Targeting

On top of increased systemic absorption chylomicrons enhance uptake in tumors and brain
New opportunities exist to generate regulatory immune cells with systemic reach

TRx Technology